<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714320</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 757456-CS4</org_study_id>
    <nct_id>NCT04714320</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood Pressure</brief_title>
  <acronym>ASTRAAS</acronym>
  <official_title>A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor of Angiotensinogen Production Administered Subcutaneously for 12 Weeks to Hypertensive Patients With Uncontrolled Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of IONIS-AGT-LRx compared to placebo on&#xD;
      systolic blood pressure (SBP) from baseline to Study Day 85 in uncontrolled hypertensive&#xD;
      participants on ≥ 3 antihypertensive medications and to evaluate the effect of IONIS-AGT-LRx&#xD;
      on SBP, diastolic blood pressure (DBP) and plasma angiotensinogen (AGT) at each scheduled&#xD;
      visit in uncontrolled hypertensive participants on ≥ 3 antihypertensive medications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a Phase 2, double-blind, randomized, placebo-controlled study in up to 150&#xD;
      participants. Participants will be randomized in a 2:1 ratio and will receive a once-weekly&#xD;
      subcutaneous (SC) treatment with either IONIS-AGT-LRx or matching placebo. The length of&#xD;
      participation in the study will be approximately 29 weeks, which includes an up to 4-week&#xD;
      screening period, a 12-week treatment period, and a 13-week post-treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Systolic Blood Pressure (SBP) from Baseline to Study Day 85</measure>
    <time_frame>Baseline to Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in plasma AGT to each scheduled, post-baseline visit</measure>
    <time_frame>Baseline up to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Study Day 85 in 24-hour mean Diastolic Blood Pressure (DBP) measured by ambulatory blood pressure monitoring (ABPM)</measure>
    <time_frame>Baseline up to Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants reaching the goals of seated automated office seated SBP ≤ 140 mmHg, DBP ≤ 90 mmHg, and both during the study</measure>
    <time_frame>Up to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants reaching the goals of automated office seated SBP ≤ 130 mmHg, DBP ≤ 80 mmHg, and both during the study</measure>
    <time_frame>Baseline up to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on seated automated office SBP to each scheduled, post-Baseline visit</measure>
    <time_frame>Baseline up to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on seated automated office DBP to each scheduled, post-Baseline visit</measure>
    <time_frame>Baseline up to Day 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Study Day 85 in 24-hour mean SBP measured by ABPM</measure>
    <time_frame>Baseline to Day 85</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>IONIS-AGT-LRx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of IONIS-AGT-LRx will be administered subcutaneously once-weekly for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IONIS-AGT-LRx-matching placebo will be administered subcutaneously once-weekly for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS-AGT-LRx</intervention_name>
    <description>Multiple doses of IONIS-AGT-LRx will be administered by SC injection.</description>
    <arm_group_label>IONIS-AGT-LRx</arm_group_label>
    <other_name>ISIS 757456</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IONIS-AGT-LRx-matching placebo will be administered by SC injection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females aged 18-80 inclusive and weighing ≥ 50 kilograms (kg) at the time of&#xD;
             informed consent&#xD;
&#xD;
          -  Females: must be non-pregnant and non-lactating, and either surgically sterile or&#xD;
             post-menopausal&#xD;
&#xD;
          -  Males must be abstinent, surgically sterile or if engaged in sexual relations with a&#xD;
             woman of childbearing potential (WOCBP), a highly effective contraceptive method must&#xD;
             be used&#xD;
&#xD;
          -  Body mass index (BMI) ≤ 45.0 kilograms per square meter (kg/m^2)&#xD;
&#xD;
          -  At screening, the participant must have been on a stable regimen (per Investigator&#xD;
             judgement) of 3 or more antihypertensive medications for at least 1 month prior to&#xD;
             screening and will be required to maintain this regimen throughout the study. The&#xD;
             combination of antihypertensive medications must be in the following categories: a)&#xD;
             angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker&#xD;
             (ARB), b) beta blocker: c) calcium channel blocker d) non-potassium sparing diuretic,&#xD;
             e) alpha-1 blocker f) centrally acting sympatholytic agent or g) direct acting&#xD;
             vasodilators (e.g. hydralazine)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant abnormalities in screening laboratory results, medical history&#xD;
             according to Investigator judgment&#xD;
&#xD;
          -  History of secondary hypertension (HTN) including, but not limited to any of the&#xD;
             following: renovascular HTN (unilateral or bilateral renal artery stenosis),&#xD;
             coarctation of the aorta, primary hyperaldosteronism, Cushing's disease,&#xD;
             pheochromocytoma, polycystic kidney disease, and drug-induced HTN&#xD;
&#xD;
          -  The use of the following at time of screening and during the course of the study:&#xD;
&#xD;
               -  Other medications for the treatment of HTN (e.g., minoxidil, diazoxide, renin&#xD;
                  inhibitors)&#xD;
&#xD;
               -  Medications that may cause hyperkalemia (e.g., cyclosporine or tacrolimus,&#xD;
                  pentamidine, trimethoprim-sulfamethoxazole, all heparins)&#xD;
&#xD;
               -  Use of oral anticoagulants, unless stable for 4 weeks prior to the first dose of&#xD;
                  study drug and regular monitoring must be performed per clinical practice during&#xD;
                  the study unless the participant is receiving vitamin K agonists. If the&#xD;
                  participant is receiving vitamin K antagonists (e.g., warfarin) international&#xD;
                  normalized ratio (INR) should be in therapeutic range, as established by the&#xD;
                  Investigator, for 4 weeks prior to the first dose&#xD;
&#xD;
               -  Chronic administration of NSAIDs or COX-2 inhibitors (except aspirin for&#xD;
                  cardiovascular disease provided the total daily dose does not exceed 325 mg)&#xD;
&#xD;
               -  Potassium sparing diuretics (e.g., eplerenone, spironolactone, amiloride,&#xD;
                  triamterene)&#xD;
&#xD;
          -  History of bleeding diathesis, coagulopathy, immune thrombocytopenic purpura (ITP),&#xD;
             thrombotic cytopenic purpura (TTP), or any qualitative or quantitative platelet defect&#xD;
&#xD;
          -  Unstable/underlying known cardiovascular disease defined as:&#xD;
&#xD;
               -  Any history of congestive heart failure (New York Heart Association [NYHA] Class&#xD;
                  III-IV)&#xD;
&#xD;
               -  Any history of previous myocardial infarction, coronary revascularization,&#xD;
                  unstable or stable angina pectoris ˂ 1 year prior to screening&#xD;
&#xD;
               -  12-lead electrocardiogram (ECG) demonstrating a QT interval (corrected using&#xD;
                  Fridericia's formula [QTcF]) ˃ 450 milliseconds (msec) in males and ˃ 470 msec in&#xD;
                  females at screening, or a history or evidence of long QT syndrome&#xD;
&#xD;
               -  Any hemodynamically unstable atrial or ventricular arrhythmias&#xD;
&#xD;
               -  Significant uncorrected valvular heart disease&#xD;
&#xD;
               -  Any history of stroke or transient ischemic attack &lt; 1 year prior to screening&#xD;
&#xD;
          -  A cardiac valve repair, cardiac device implantation, and/or a hospitalization for&#xD;
             heart failure within 3 months of screening&#xD;
&#xD;
          -  Active infection requiring systemic antiviral or antimicrobial therapy that will not&#xD;
             be completed prior to Study Day 1&#xD;
&#xD;
          -  Participant works nighttime shifts (e.g., 11 PM to 7 AM)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ionis Pharmaceuticals</last_name>
    <phone>(844) 414-1754</phone>
    <email>ionisNCT04714320study@clinicaltrialmedia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pinnacle Research Group</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cahaba Research, Inc.</name>
      <address>
        <city>Pelham</city>
        <state>Alabama</state>
        <zip>35124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Studies</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cardiology and Medicine Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Research Center</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Huntington Park</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>RESPIRE Research</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Fernando Valley Health Institute</name>
      <address>
        <city>Van Nuys</city>
        <state>California</state>
        <zip>91405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Creekside Endocrine Associates, PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chase Medical Research LLC</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ALL Medical Research, LLC</name>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research - Crystal River</name>
      <address>
        <city>Crystal River</city>
        <state>Florida</state>
        <zip>34429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>East Coast Institute for Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AMPM Research Clinic</name>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute Inc</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gwinnett Research Institute</name>
      <address>
        <city>Buford</city>
        <state>Georgia</state>
        <zip>30519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgia Institute for Clinical Research</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eagle Clinical Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Specialists, Inc. - Wauconda</name>
      <address>
        <city>Wauconda</city>
        <state>Illinois</state>
        <zip>60084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Management LLC - Southshore</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Louisiana Heart Center</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America, LLC - Monroe, LA</name>
      <address>
        <city>West Monroe</city>
        <state>Louisiana</state>
        <zip>71291</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BioPharm Clinical Research</name>
      <address>
        <city>Caro</city>
        <state>Michigan</state>
        <zip>48723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Palm Research Center, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NY Scientific</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Summit Research Group, LLC</name>
      <address>
        <city>Stow</city>
        <state>Ohio</state>
        <zip>44224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Oklahoma Heart Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Newton Clinical Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73159</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Health Concepts Research</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chattanooga Research &amp; Medicine, PLLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juno Research, LL</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Protenium Clinical Research, LLC</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Laguna Clinical Research Associates</name>
      <address>
        <city>Laredo</city>
        <state>Texas</state>
        <zip>78041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kalo Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manassas Clinical Research Center</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>York Clinical Research LLC</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>TPMG Clinical Research</name>
      <address>
        <city>Williamsburg</city>
        <state>Virginia</state>
        <zip>23188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Bloch</last_name>
      <email>dawn.bloch1@tpmgpc.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Hypertensive</keyword>
  <keyword>AGT</keyword>
  <keyword>Angiotensinogen</keyword>
  <keyword>Blood Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

